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Use of haploidentical stem cell transplantation continues to
increase: the 2015 European Society for Blood and Marrow
Transplant activity survey report
JR Passweg1, H Baldomero1, P Bader2, C Bonini3, RF Duarte4, C Dufour5, A Gennery6, N Kröger7, J Kuball8, F Lanza9, S Montoto10,
A Nagler11, JA Snowden12, J Styczynski13 and M Mohty14 for the European Society for Blood and Marrow Transplantation (EBMT)
Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the
hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were
reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with
the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income
countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25%; 96% allogeneic), lymphoid malignancies
24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic).
Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new
drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005. Growth is
seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both
marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.
Bone Marrow Transplantation (2017) 52, 811–817; doi:10.1038/bmt.2017.34; published online 13 March 2017
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is an established
procedure for many acquired and congenital disorders of the
hematopoietic system, including disorders of the immune system,
and as enzyme replacement in metabolic disorders.1–4 The annual
activity survey of the European Society of Blood and Marrow
Transplantation (EBMT), describing the status of HSCT in Europe
and affiliated countries, has become an instrument used to
observe trends and to monitor changes in technology use.5–12 The
survey captures the numbers of HSCT performed in the preceding
year by each participating team, divided by indication, donor type
and stem cell source. The standardized structure of the survey
over many years and the excellent commitment of the participat-
ing teams allow us to observe changes over time and to evaluate
factors associated with these changes. More recently, the survey
has included additional information on novel cell therapies with
hematopoietic stem cells for non-hematopoietic use, as well as on
the use of non-hematopoietic stem and progenitor cells. This
coincides with the recent interest of the World Health Organiza-
tion (www.who.org) in cell and tissue transplants, and further
stresses the need for adequate and timely information.13 The
analysis of the survey data spanning over 25 years and amassing
data on more than 600 000 transplants in over 550 000 patients,
has shown a continued and constant increase in the annual
numbers of HSCT and transplant rates (number of HSCT/10 million
inhabitants) for both allogeneic and autologous HSCT.
This report is based on the 2015 survey data. In addition to
transplant rates and indications, this report focuses on the use
of haploidentical donors for transplantation including disease
entities and stem cell sources.
PATIENTS AND METHODS
Data collection and validation
Participating teams were invited to report data for 2015 by
indication, stem cell source and donor type as listed in Table 1.
The survey allows the possibility to report additional information
on the numbers of subsequent transplants performed as a result
of relapse, rejection or those that are part of a planned sequential
transplant protocol. Supplementary Information on the numbers
of donor lymphocyte infusions, reduced intensity HSCT and the
numbers of pediatric HSCT is also collected. New in this year’s
survey is the more detailed report on cellular therapies (Table 2).
Quality-control measures included several independent systems:
confirmation of validity of the entered data by the reporting team,
selective comparison of the survey data with minimum essential
data (MED-A) data sets in the EBMT Registry database and cross-
checking with the National Registries.
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Teams
Six hundred and eighty-seven centers from 48 countries were
contacted for the 2015 survey (39 European and 9 affiliated
countries), of which 655 teams reported. This corresponds to a
95% return rate and includes 552 active EBMT member teams.
Thirty-two active teams failed to report in 2015.
Contacted teams are listed in the online Supplementary
Appendix in alphabetical order by country, city and EBMT centre
code, with their reported numbers of first and total HSCT, and of
first allogeneic and autologous HSCT as Supplementary Material.
The World Health Organization regional office definitions
(www.who.org) were used to classify countries as European or
Non-European. Nine non-European countries participated in the
2015 EBMT survey: Algeria, Iran, Israel, Jordan, Lebanon, Nigeria,
Saudi Arabia, South Africa and Tunisia. Their data (2776 HSCT in
2657 patients) from 29 actively transplanting teams make up 6.6%
of the total data set and is included in all analyses.13
Patient and transplant numbers
Wherever appropriate, patient numbers corresponding to the
number of patients receiving a first transplant and transplant
numbers reflecting the total number of transplants performed are
listed.
The term sibling donor includes HLA identical siblings and
twins, but not siblings with HLA mismatches. Unrelated donor
transplants include HSCT from unrelated donors with peripheral
blood and marrow as a stem cell source, but not cord blood HSCT.
In the 2015 survey, we collected separately the numbers of haplo-
identical and other family member HSCT. Haplo-identical being
described as any family member with two or more loci mismatch
within the loci HLA-A, -B, -C, -DRB1 and -DQB1 in GvH and/or HvG
direction. Other family member donors are those related donors
who are mismatched to a lesser degree than a full haplotype.
Additional non-first transplants may include multiple transplants
defined as subsequent transplants within a planned double
or triple autologous or allogeneic transplant protocol, and
retransplants (autologous or allogeneic) defined as unplanned
HSCT for rejection or relapse after a previous HSCT.
Transplant rates
Transplant rates, defined as the total number of HSCT per
10 million inhabitants, were computed for each country without
adjustments for patients who crossed borders and received
their HSCT in a foreign country. Population numbers were
obtained from Eurostats for 2015 for the European countries,
(http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_ure




Wherever appropriate, the absolute numbers of transplanted
patients, transplants or transplant rates are shown for
specific countries, indications or transplant techniques. Myeloid
malignancies include AML, myelodysplastic or myelodysplastic/
myeloproliferative neoplasm (MPN), MPN and CML. Lymphoid
malignancies include ALL, CLL, Hodgkin’s disease, non-Hodgkin
lymphoma and plasma cell disorders. The non-malignant dis-
orders include bone marrow failure, thalassemia, sickle cell
disease, primary immune disease inherited disease of metabolism
and autoimmune disease AID. Others include histiocytosis and
other rare disorders not included in the above.
RESULTS
2015 data
Participating teams in 2015. Of the 655 teams, 412 (62%)
performed both allogeneic and autologous transplants; 227
(35%) restricted their activity to autologous HSCT and 11 teams
(2%) to allogeneic transplants only. Five teams (1%) reported
having performed no transplants in 2015 due to renovation or
temporary closure of the transplant unit. Of the 655 active centers,
131 (20%) centers performed transplants on both adult and
pediatric patients. An additional 106 (16%) centers were dedicated
pediatric transplant centers and 417 (64%) centers performed
transplants on adults only.
Numbers of patients and transplants
In 2015, 42 171 transplants were reported in 37 626 patients (first
transplant); of these, 17 302 HSCT (41%) were allogeneic and
24 869 (59%) autologous (Table 1). When compared with that in
2014, the total number of transplants increased by 3.3%
(2.1% allogeneic HSCT and 4.1% autologous HSCT).12 Furthermore,
there were 4545 second or subsequent transplants, 1272
allogeneic and 3273 autologous. The total number of patients
transplanted under the age of 18 in both dedicated and joint
adult-pediatric units was 4490 (3338 allogeneic and 1152
autologous HSCT). Of these, 3015 patients (67%, 2570 allogeneic
and 896 autologous) reporting a total of 3466 transplants were
performed in dedicated pediatric centers. A total of 4545
transplants were second or multiple transplants. Among these,
Table 2. Numbers of cellular therapies in Europe 2015 by indication, donor type and cell source

















Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto
GvHD 396 3 29 1 3
Graft enhancement 803 44 1 2 14 5 24
Autoimmune disease 4 40
Genetic disease 2 1 8
Infection 4 119 6
Malignancy 1 11 1 32 5 1 5 8 4 5 20 19 3
DLI for residual disease 410
DLI for relapse 1285
DLI per protocol 442
Regenerative medicine 16 7 1 3 94
Total 2940 467 48 13 1 168 5 30 5 9 5 5 20 9 0 19 8 33 97
Abbreviations: DLI=donor lymphocyte infusions; MSC=mesenchymal stem cells; NK=natural killer; TREGS= regulatory T cells. Bold text implies the totals.
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3273 were autologous, the majority of which were probably part
of multiple transplant programs, for example, as for plasma cell
disorders. In total, 1272 were allogeneic HSCTs mainly to treat
relapse or graft failure. In addition, 794 HSCTs were reported as
allogeneic HSCT after a previous autologous HSCT and were
mainly for lymphoma or plasma cell disorders.
Indications
Indications for HSCT in 2015 are listed in detail in Table 1.
Main indications were myeloid malignancies (AML, CML,
myelodysplastic/MPN and MPN): 9413 (25% of total; 96% of which
were allogeneic); lymphoid malignancies (ALL, CLL, Hodgkin’s
disease, non-Hodgkin lymphoma and plasma cell disorder): 24 340
(65%; 20% allogeneic); solid tumors: 1516 (4%; 3% allogeneic); non-
malignant disorders: 2208 (6%; 90% allogeneic) and others: 149
(0.4%). As seen in previous years, the majority of HSCT for lymphoid
malignancies were autologous, whereas most transplants for
leukemia were performed using stem cells from allogeneic donors.
Autologous HSCT for non-malignant disorders predominantly
include patients with autoimmune disorders (207).
Figures 1a and b show as a pie graph the distribution of disease
indications for allogeneic (Figure 1a) and autologous (Figure 1b),
respectively. Of interest, we show that for allogeneic HSCT AML is
the most frequent indication (39%); of these, 21% were for
patients in CR1, 12% for patients with more advanced disease and
6% for patients with transformed AML, either therapy related or
from myelodysplastic /MPN. Compared with that in 2014, there
were increases in allogeneic HSCT for AML by 7.9% and MPN 3.5%
and a major decrease by 28% was seen in allogeneic HSCT use
for CLL (Figure 2), dropping from 504 patients in 2011 to 255 in
2015. Among allogeneic HSCT, 6933 were performed using
non-myeloablative conditioning. This is an increase of 1% since
in 2014 and is 40% of all allogeneic HSCT. For autologous HSCT,
there was an increase in myeloma by 8.1% and Hodgkin
lymphoma by 2.1%; proportions for most other diseases remained
stable.
Important trends in 2015 include continued increase in patients
treated with allogeneic and autologous HSCT as shown in
Supplementary Figure 1, and increasing use among allogeneic
HSCT recipients of unrelated donor transplantation,14 although
it might appear that the growth rate is slowing down
(Supplementary Figure 2). Figure 3a shows the continued use of
alternative donor transplantation and among these an impressive
increase of the use of haploidentical donors to 2012 patients in
2015 across Europe, an increase of 291% since 2005. The highest
growth is seen in myeloid malignancies (1008), with lymphoid
malignancies 636, nonmalignant disorders 316 and 52 others.
Figure 3b shows that the growth of haploidentical donor HSCT is
seen more in patients with myeloid malignancy, but also in
lymphoid malignancy and non-malignant disorders, although to a
lesser degree. Among myeloid malignancies, the majority (n= 735)
are patients with AML. Of note, there are equal proportions of
patients with AML receiving haploidentical donor HSCT trans-
planted in CR1 and with more advanced disease (Figure 3c).
Stem cell source for haploidentical donor HSCT is shown in
Figure 3d, peripheral blood is used more frequently than marrow.
The decreasing use of unrelated cord blood as donor source is
shown in Figure 3a for total HSCT, or by main indication in
Figure 3e. This decrease is in sharp contrast to the rise seen in
haploidentical donor HSCT. As shown in Figure 3e, this decrease
pertains to myeloid and lymphoid malignancies but not to
nonmalignant disorders where the use of unrelated cord blood is
stable over time.
Transplant rates
Supplementary Figures 3a and b show transplant rates by country



































Figure 1. Relative proportion of indications for HSCT in Europe in 2015. (a) Proportions of disease indications for allogeneic HSCT in Europe in















Figure 2. The rise and fall in absolute numbers of allogeneic HSCT
for CLL in Europe 1990–2015.
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maps of Europe. Median transplant rates per 10 million inhabitants
were 153.1 (range, 4.4–460.9) for allogeneic HSCT and 251.8
(range, 1.0–759.9) for autologous HSCT in 2015. For the purpose
of this analysis, we have grouped countries according to
World Bank income group gross national income per capita in
USD in 2015, (http://data.worldbank.org/data-catalog/world-devel
opment-indicators). All European countries fall within the group of
either middle-income or high-income category; thus, we created a
third group to split the high-income countries into very wealthy
countries defined as 440 000 USD gross national income per
capita. Median transplant rates in 2015 for the 3 groups are as
follows: 262, 179, and 34 for very-high-, high- and medium-income
countries (allogeneic HSCT, transplants per 10 million inhabitants),
and 396, 295 and 56 for autologous HSCT, respectively. Figure 4
shows growth rates in allogeneic and autologous HSCT use by
income category as relative growth, that is, % increase from 2005
to 2015 or as absolute increase in transplant rates from 2005 to
2015 normalized for size of the population. Figure 4a and b shows
that % increase is highest for middle income countries (gross
national income per capitao12 500 USD) for both allogeneic and
autologous HSCT, and lowest for the very-high-income countries.
The higher income countries had already achieved a high level of
transplant rates in 2005. To the contrary, the absolute growth, that
is, increase in access of patients to transplant centers is highest in
2500
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Figure 3. Change in the absolute numbers of haploidentical and cord blood HSCT in Europe 1990–2015. (a) Change in donor selection from
cord blood HSCT to haploidentical HSCT. (b) Increase in the use of haploidentical donors by main indication group. (c) Haploidentical HSCT by
AML early disease and advanced disease. (d) Haploidentical HSCT by cell source; bone marrow versus peripheral blood. (e) Trend in the use of
unrelated cord blood HSCT by main indication group 2006–2015.
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the very-high-income countries in the period of 2005–2015, again
for both allogeneic and autologous HSCT.
Additional cellular therapies
A total of 35 countries (330 teams) reported having performed
3882 cellular therapies in 2015. Of these, 2940 patients received
donor lymphocyte infusions (Table 2). Indications were graft
enhancement: 803 (27%), residual disease: 410 (14%), relapsed
disease: 1285 (44%), and per protocol 442 (15%).
Other cellular therapies were given either within the context of
a HSCT or not. The majority were mesenchymal stem cells given
for GvHD treatment (396) of for graft enhancement (45). Seventy-
four patients received mesenchymal stem cells for various other
indications. The largest additional group of cellular therapies were
selected or expanded T cells given to treat infectious complica-
tions (119 patients) or for anti-malignant effects (37). Other cellular
therapies including natural killer cells,14 regulatory T-cells (35),
genetically modified T-cells,14 dendritic cells (25) and expanded or
genetically modified hematopoietic stem cells (36) were reported
more rarely. One hundred and twenty-one patients received
cellular products for purposes of regenerative medicine.15,16
DISCUSSION
The EBMT activity survey has been conducted annually since
1990.6 The 2010 survey reported for the first time 430 000
patients transplanted in a given year17 and440 000 transplants in
2014. Again, transplant numbers continue to increase unabated
across Europe.
HSCT for some indications continues to increase but not for
others. Of interest is the decreasing use of allogeneic HSCT for CLL
and a growth in allogeneic HSCT using haploidentical donors, an
increase over 200% in the last 5 years. The drop in allogeneic HSCT
for CLL is remarkable and reminds us of the drop seen in CML
transplants once kinase inhibitors became available.18,19 Whether
this drop is going to be permanent or whether this is temporary
will depend on the long-term results of kinase inhibitors and
possibly bcl2 inhibitors developed to treat CLL.
The continuing use of haploidentical donors is impressive and it
becomes apparent that haploidentical donor HSCT is not only used
for advance disease stages but also for early disease stages as
exemplified by AML (Figure 3c). The use of peripheral blood as a
stem cell source has surpassed the use of marrow (Figure 3d),
although the original studies describing haploidentical donor HSCT
with post-transplant cyclophosphamide as GvHD prophylaxis have
been using mainly marrow.20 The use of unrelated cord blood, a
competitor for alternative donor HSCT when identical siblings and
well-matched unrelated donors are not available, continues to
decrease but only for malignant disorders.21 Cord blood transplant
rates for nonmalignant diseases remain stable, reflecting the
practice mainly in pediatric centers.
We looked at development of transplant technology in
countries in Europe by economic strength of the societies and,
for this purpose, show growth of allogeneic and autologous
HSCT as relative and as absolute growth for countries in the
middle-, high- and very-high-income categories. We here confirm
that the relative growth is more significant in middle income
countries, but that the highest absolute growth over the last
decade is seen in the category of very-high-income countries. This
exemplifies that autologous and allogeneic HSCT remains an
expensive technology broadly available in wealthy societies.
We have added data on the use of cellular therapies, most of
which is donor lymphocyte infusions given to treat relapse or
residual disease in over 2900 patients. Other cellular therapies
have been given to over 900 patients, the largest group of which
is mesenchymal stromal cells to treat GvHD. Although we have
established confidence in the reported transplant numbers we
cannot exclude a certain degree of underreporting, particularly in
the most advanced fields of cellular therapies of patients included
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Figure 4. Effect of income group on changes in transplant activity and transplant rates 2005–2015. (a) Percentage increase in transplant
activity for allogeneic HSCT (top left), increase in transplant rates for allogeneic HSCT (bottom left). (b) Percentage increase in transplant
activity for autologous HSCT (top right), increase in transplant rates for autologous HSCT (bottom right).
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In conclusion, this year’s activity survey shows continued
increase in the use of HSCT across Europe. Some trends are
visible and are discussed here. The study reflects current practice
and results may be useful to healthcare planning and health policy
makers.
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